The first reaction of many patients after being diagnosed with breast cancer is “save your life first and cut off your breast”, “breast-conserving treatment is prone to recurrence, removing the breast is cleaner and more thorough”, “breast-conserving treatment may have the possibility of recurrence, it is better to remove the breast”. The better” ……, not to mention patients, many doctors have this view, think that all cut naturally safer. –This idea, however, has never been proven correct by the academic community, it has just been assumed by everyone; however, unfortunately, just this week, this conclusion was proven wrong – clinical trials have proven that patients with breast conservation + radiotherapy can obtain higher survival rate than mastectomy. Zhang Bin, Department of Breast Oncology, Tianjin Cancer Hospital A paper in Cancer, one of the most authoritative journals in oncology, this week showed that patients with early-stage breast cancer who receive breast-conserving treatment (local lesion excision + radiotherapy) can achieve a higher survival rate and longer survival time compared to mastectomy. The article’s author, Shelley Hwang of the Duke Cancer Institute, said, “Although we have not yet figured out why mastectomized patients have a higher risk of death than breast-conserving patients, the findings show that breast-conserving therapy is still an extremely promising and effective treatment even for early-stage breast cancer. ” Over the past decade, many breast cancer patients have opted for mastectomy, and even early-stage breast cancer patients often choose to have their breasts removed. Some do so out of medical necessity, while others do so out of psychological fear or rumor. Patients who have not been carefully prepared for mastectomy have a preconceived notion that mastectomy has a better chance of survival than breast-conserving surgery. In the review, Hwang said, “Breast-conserving surgery is always an excellent option for all patients with early-stage breast cancer, regardless of their age and tumor type.” In the study, Hwang and their colleagues included 112,000 patients with stage I-II breast cancer in California who were diagnosed between 1990 and 2004, underwent mastectomy or breast-conserving surgery + radiation therapy, and were followed until 2009, and they analyzed the association between treatment modality and survival rates. Hwang suggested that perhaps the patients who had breast-conserving treatment were in better health. Throughout the study period, patients who received breast-conserving surgery + radiation therapy had better survival rates than those who received mastectomy. In fact, the breast-conserving + radiotherapy group had better survival than mastectomy for patients of any age group and tumor type. Patients aged 50 years or older with estrogen and progesterone receptor-positive breast cancer had the greatest benefit with breast-conserving treatment. The researchers observed that patients had a 14% lower risk of dying from breast cancer during the follow-up period than patients with similar clinical conditions who had mastectomy-that is, breast-conserving treatment reduced the risk of death by 14%. The reasons and mechanisms for the superior efficacy of breast-conserving treatment over mastectomy have not been explored in depth by researchers. The treatment choices patients need to make are related to whether their disease recurs, and I think patients’ choices will undoubtedly be influenced when they know that survival rates are better with breast-conserving treatment in early-stage breast cancer. Breast-conserving treatment here is not simply a treatment without mastectomy, but a standard procedure that is more elaborate and complex than mastectomy, a standardized breast-conserving procedure performed at a larger comprehensive breast center with specialized breast imaging, breast surgery, breast pathology, and breast medicine, rather than a simple procedure with a random cut. It is a standardized procedure of breast-conserving surgery in a large comprehensive breast center with specialized breast imaging, breast surgery, breast pathology and breast medicine. Dr. Zhang Bin, Department of Breast Surgery, Tianjin Cancer Hospital, China Microsignal:eeflying